Lifting the spirits of patients, medical practiticioners and investors, San Francisco-based VistaGen Therapeutics (NASDAQ:VTGN) came out with exciting news Monday.
The clinical-stage biopharmaceutical company, developing new generation medicines for depression, social anxiety disorder and other central nervous system diseases and disorders with high unmet need, announced today additional results from a positive pilot Phase 3 study of PH94B, a potential first-in-class neuroactive nasal spray shown to be effective on an as-needed basis for treatment of social anxiety disorder.
The new data were presented in a poster session at the 2019 Anxiety and Depression Association of America Annual Conference in Chicago.
Dr. Michael Liebowitz, who headed the study "Social anxiety disorder is one of the most prevalent mental health conditions in the U.S., affecting as many as 15 million Americans. In both Phase 2 and pilot Phase 3 clinical studies, PH94B was more effective than placebo in the whole sample on the primary outcome measure."
Shares took the cue, and galloped 4.7 cents, or 3.7%, to $1.33, on volume of 345,000 shares.
